文献速递胸部肿瘤放疗

立体定向体部放疗对比常规分割放疗治疗早期非小细胞肺癌

Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer.
PubMed 文献 · Radiother Oncol · 2018-07-18

基于美国国家癌症数据库(2004-2015年)23,088例cT1-2aN0M0非小细胞肺癌患者,其中2,286例(10%)接受常规分割放疗、20,802例(90%)接受立体定向体部放疗。立体定向体部放疗组中位总生存为38.8个月,常规分割放疗组为28.1个月(P<0.001),倾向匹配后结果持续。

要点

  • 在23,088例早期非小细胞肺癌中,90%接受立体定向体部放疗,10%接受常规分割放疗。
  • 立体定向体部放疗组中位总生存38.8个月,常规分割放疗组28.1个月(P<0.001)。
  • 倾向匹配后生存差异持续存在,Cox多因素分析中立体定向体部放疗与总生存独立相关(P<0.001)。

核心结论

  • 这项迄今最大规模的研究(超过23,000例患者)显示,消融放疗对早期非小细胞肺癌具有生存获益。
  • 作者表示热切期待对比性前瞻性试验的成熟结果。

研究设计与样本

  • 查询美国国家癌症数据库(2004-2015年),纳入组织学确诊的cT1-2aN0M0非小细胞肺癌并接受根治性常规分割放疗或立体定向体部放疗的患者。
  • 共纳入23,088例患者,其中2,286例(10%)接受常规分割放疗,20,802例(90%)接受立体定向体部放疗。
  • 采用多因素logistic回归分析立体定向体部放疗实施的相关因素,Kaplan-Meier法评估倾向匹配前后的总生存,Cox比例风险模型确定与总生存相关的变量。

主要发现

  • 立体定向体部放疗较少用于非裔美国人、低收入患者、城市地区、合并症较多者、非学术中心、较大肿瘤及鳞状细胞组织学类型(所有P<0.05)。
  • 立体定向体部放疗组中位总生存为38.8个月,常规分割放疗组为28.1个月(P<0.001)。
  • 中位随访44.6个月时,立体定向体部放疗组中位总生存为38.8个月,常规分割放疗组为28.1个月(P<0.001),倾向匹配后结果持续存在。
  • 亚组分析显示多个亚组(T2期、Charlson合并症评分2-3分、鳞状细胞组织学类型)中总生存改善。
  • Cox多因素分析中立体定向体部放疗与总生存独立相关(P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To date, no published randomized trials have shown stereotactic body radiation therapy (SBRT) to offer superior outcomes to conventionally fractionated radiation therapy (CFRT) for early-stage non-small cell lung cancer (NSCLC). The largest study to date, this investigation of a contemporary national database sought to evaluate practice patterns and survival between CFRT and SBRT. METHODS: The National Cancer Database was queried (2004-2015) for histologically-confirmed cT1-2aN0M0 NSCLC undergoing definitive CFRT or SBRT. Multivariable logistic regression ascertained factors associated with SBRT administration. Kaplan-Meier analysis evaluated overall survival (OS) before and following propensity matching. Cox proportional hazards modeling determined variables associated with OS. RESULTS: Of 23,088 patients, 2286 (10%) patients received CFRT and 20,802 (90%) SBRT. SBRT was less often delivered in African-Americans, patients with lower incomes, urban location, greater comorbidities, at non-academic centers, in larger tumors, and squamous histology (p < 0.05 for all). Patients treated with SBRT had a higher median OS (38.8 months vs. 28.1 months, p < 0.001). At median follow-up of 44.6 months, the median OS for the SBRT group was 38.8 months, versus 28.1 months for CFRT (p < 0.001). These findings persisted following propensity matching. Subgroup analyses demonstrated improved OS in multiple subcohorts (T2, Charlson comorbidity score 2-3, squamous histology). SBRT was also independently associated with OS on Cox multivariate analysis (p < 0.001). CONCLUSIONS: The largest such study to date (comprising of over 23,000 patients), this investigation demonstrates the survival benefit to ablative radiotherapy for early-stage NSCLC. Maturation of comparative prospective trials is eagerly awaited.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Haque W, Verma V, Polamraju P, et al. Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer. Radiother Oncol. 2018. PMID: 30031630. doi:10.1016/j.radonc.2018.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。